Evaluation ofSalmonella entericaserovar Typhi (Ty2aroC-ssaV-) M01ZH09, with a defined mutation in theSalmonellapathogenicity island 2, as a live, oral typhoid vaccine in human volunteers

• Published in: Vaccine Vol. 24; no. 2; p. 116
• Main Authors: Kirkpatrick, BD, McKenzie, Robin, O'Neill, J Patrick, Larsson, Catherine J, Bourgeois, A Louis, Shimko, Janet, Bentley, Matthew, Makin, Jill, Chatfield, Steve, Hindle, Zoë, Fidler, Christine, Robinson, Brad E, Ventrone, Cassandra H, Bansal, Nivedita, Carpenter, Colleen M, Kutzko, Deborah, Hamlet, Sandra, LaPointe, Casey, Taylor, David N
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 12-01-2006
• Subjects: Immune response; Immunization; Immunogenicity; Mutation; Salmonella; Temperature measurement; Typhoid; Vaccines
• DOI: 10.1016/j.vaccine.2005.08.008
• EISSN: 1873-2518
• ISSN: 0264-410X

Salmonella entericaserovar Typhi strains with mutations in theSalmonellapathogenicity island-2 (SPI-2) may represent an effective strategy for human vaccine development, and a vectoring system for heterologous antigens.S.Typhi (Ty2aroC-ssaV-) M01ZH09 is an attenuated, live, oral typhoid vaccine harboring defined deletion mutations inssaV, which encodes an integral component in the SPI-2 type III secretion system (TTSS), as well as a mutation in an aromatic biosynthetic pathway needed for bacterial growth in vivo (aroC). SPI-2 mutant vaccines have yet to be evaluated in a large, randomized human trial. A simplified or single-oral dose oral typhoid vaccine using the SPI-2 strategy would offer significant advantages over the currently licensed typhoid vaccines. We performed a double-blinded, placebo-controlled, dose-escalating clinical trial in 60 healthy adult volunteers to determine the tolerability and immunogenicity of a single dose of M01ZH09. Three groups of 20 healthy adult volunteers were enrolled; 16 in each group received a single oral dose of the freeze-dried vaccine at 5x107, 5x108or 5x109CFU in a bicarbonate buffer. Four volunteers in each cohort received placebo in the same buffer. Adverse events were infrequent and not statistically different between vaccine and placebo recipients, although two subjects in the mid-range dose and three subjects in the highest dose had temperature measurements >37.5°C. No blood or urine cultures were positive for M01ZH09, and fecal shedding was brief. The immune response was dose-related; the highest vaccine dose (5x109CFU) was the most immunogenic. All tested subjects receiving the highest dose had a significant ASC response (mean 118 spots/106cells). A >=4-fold increase in antibody titer forS.Typhi LPS or flagellin was detected in 75% of volunteers in the highest-dose cohort by day 28. The SPI-2 mutant vaccine, M01ZH09, is a promising typhoid vaccine candidate and deserves further study as a vectoring system for heterologous vaccine antigens.